We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division

THERMO FISHER SCIENTIFIC

  Gold Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Thermo Fisher Launches CE-IVD-Marked Next-Generation TaqPath COVID-19 2.0 Test

By LabMedica International staff writers
Posted on 23 Jun 2021
Print article
Image: TaqPath COVID-19 Fast PCR Combo Kit 2.0 (Photo courtesy of Thermo Fisher Scientific Inc.)
Image: TaqPath COVID-19 Fast PCR Combo Kit 2.0 (Photo courtesy of Thermo Fisher Scientific Inc.)
Thermo Fisher Scientific Inc. (Waltham, MA, USA) has launched a new CE-IVD-marked COVID-19 test named the TaqPath COVID-19 Fast PCR Combo Kit 2.0., expanding its menu of highly accurate tests that detect active SARS-CoV-2 infections.

The kit uses an advanced assay design which compensates for current and emerging variants by using eight total targets across three genomic regions of the virus. This approach helps to ensure the test provides accurate results even as the virus that causes COVID-19 continues to mutate. The TaqPath COVID-19 Fast PCR Combo Kit 2.0 test assesses raw saliva directly with a turnaround time of two hours to enable widespread, high-frequency testing. The first generation TaqPath COVID-19 CE-IVD RT PCR Kit and the TaqPath COVID-19 Combo Kit, which use a different assay design, respectively, received initial CE-IVD certification and Emergency Use Authorization from the U.S. Food and Drug Administration (FDA) in March 2020.

"COVID-19 variants can be more transmissible and potentially impact efficacy of diagnostics, vaccines and therapies, threatening to reverse progress made in the past year," said Manoj Gandhi, M.D., Ph.D., senior medical director, genetic sciences for Thermo Fisher. "We are working to empower our customers to prepare for the next stage of the pandemic by future-proofing our test design against likely mutations and to provide continued confidence in their results."

Related Links:
Thermo Fisher Scientific Inc.

New
Gold Supplier
COVID-19 TEST READER
COVID-19-CHECK-1 EASY READER+
New
Cooling System
Cryolys Evolution
New
COVID-19 IgM/IgG Antibody Test
MosaiQ COVID-19 Antibody Microarray
New
Immunoassay Analyzer
AFIAS-1

Print article

Channels

Molecular Diagnostics

view channel
Image: Primary angle closure glaucoma can cause permanent blindness if not treated quickly. A highly sensitive genetic test has been developed (Photo courtesy of Flinders University)

Highly Sensitive Genetic Test for Glaucoma Developed

In open-angle glaucoma, the angle in the eye where the iris meets the cornea is as wide and open as it should be, but the eye’s drainage canals become clogged over time, causing an increase in internal... Read more

Industry

view channel
Illustration

ELITechGroup Acquires Freezing Point Osmometry Provider GONOTEC

ELITechGroup (Puteaux, France) has acquired GONOTEC (Berlin, Germany), thus uniting two osmometry market leaders. The acquisition will also provides the industry with a full range of osmometry solutions... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.